Xuesen Zhang
Nanjing Medical University
32 Papers
24 Citations
Xuesen Zhang is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Citrullination & Histone. The author has an hindex of 15, co-authored 29 publications. Previous affiliations of Xuesen Zhang include Cornell University.
Chat about Author
Papers
Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation
Xuesen Zhang,Michael J. Bolt,Michael J. Guertin,Wei Chen,Sheng Zhang,Brian D. Cherrington,Daniel J. Slade,Cchristina J. Dreyton,Venkataraman Subramanian,Kevin L. Bicker,Paul R. Thompson,Michael A. Mancini,John T. Lis,Scott A. Coonrod +13 more
TL;DR: In this article, the authors found that E2-positive cells with 17β-estradiol (E2) promoted global citrullination of histone H3 arginine 26 (H3R26) on chromatin.
Synthesis and Screening of a Haloacetamidine Containing Library To Identify PAD4 Selective Inhibitors
Justin E. Jones,Jessica L. Slack,Pengfei Fang,Xuesen Zhang,Venkataraman Subramanian,Corey P. Causey,Scott A. Coonrod,Min Guo,Paul R. Thompson +8 more
TL;DR: A library approach was used to identify PAD-selective inhibitors and the identification of Thr-Asp-F-amidine (TDFA) as a highly potent PAD4 inactivator that displays ≥15-fold selectivity for P AD4 versus P AD1 and ≥50-fold versus PADs 2 and 3 is described.
Genome-Wide Analysis Reveals PADI4 Cooperates with Elk-1 to Activate c-Fos Expression in Breast Cancer Cells
Xuesen Zhang,Matthew J. Gamble,Matthew J. Gamble,Sonja C. Stadler,Brian D. Cherrington,Corey P. Causey,Paul R. Thompson,Mark S. Roberson,W. Lee Kraus,Scott A. Coonrod +9 more
TL;DR: It is shown that PADI4 interacts with Elk-1 at the c-Fos promoter and that, following Epidermal Growth Factor stimulation, PADi4 catalytic activity facilitates Elk- 1 phosphorylation, histone H4 acetylation, and c-fos transcriptional activation, which defines a novel role for P ADI4 as a transcription factor co-activator.
Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Fujun Li,Lixia Miao,Teng Xue,Hao Qin,Santanu Mondal,Paul R. Thompson,Scott A. Coonrod,Xiaoqiu Liu,Xuesen Zhang +8 more
TL;DR: PAD2 functions as an important new biomarker for tamoxifen-resistant breast cancers and that inhibiting PAD2 combined with docetaxel may offer a new approach to treatment of tamoxIFen- resistant breast cancers.
PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
Hao Qin,Xiaoqiu Liu,Fujun Li,Lixia Miao,Tingting Li,Boqun Xu,Xiaofei An,Aaron Muth,Paul R. Thompson,Scott A. Coonrod,Xuesen Zhang +10 more
TL;DR: The data indicate that PAD1 appears to promote tumorigenesis by regulating MEK1-ERK1/2-MMP2 signaling in TNBC, and raises the possibility that Pad1 may function as an important new biomarker for TNBC tumors and suggest that P AD1-specific inhibitors could potentially be utilized to treat metastatic breast cancer.
79